Insider buying last 90 days
No open-market insider purchases were filed for BMRN in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
BioMarin's third-quarter 2026 revenue rose to $1,024.6 million, up from $776.1 million a year earlier, driven by sales of Galafold and Pombiliti + Opfolda following the Amicus acquisition, though the quarterly net loss widened. H.C. Wainwright reiterated a Neutral rating with a $60.00 price target, citing caution on Voxzogo's U.S. retention ahead of potential oral competition and before hypochondroplasia revenue contributes. The company also announced management will present at three November investor conferences, and traders acquired an unusually large volume of call options on 4 November.
BMRN closed at $57.18, up 2.1%, sitting between its 50-day average of $59.54 and 200-day average of $58.45. The GekkoIndex reads 58.7, in the Neutral zone, down 0.5 over five sessions. Shares trade 12.6% below Gekko Fair Value of $65.39, with a 52-week range of $49.26 to $70.98 and a three-month return of -17.8%.
The next earnings report is scheduled for 22 February 2027, 99 days away, placing it outside a typical 20-trading-day holding window. Over the last 30 days, one unusual options signal was recorded, with call premium of $339,327 against no put premium. One billionaire holder is noted, with no trailblazer holders. Seasonally, the next 20 trading days have averaged +8.5% over five years, rising in 5 of them. Analyst consensus across 22 firms includes 16 buy and 6 hold ratings, with a consensus target of $91.04.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
BioMarin Pharmaceutical scores 4 supportive, 2 mixed and 0 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive2 mixed0 headwinds
Averages disagree
Close $57.23 sits between the 50-day ($58.86) and 200-day ($58.46) averages, or the averages disagree.
See the chart57.6, Neutral
Reading 57.6 is in the Neutral zone.
See the GekkoIndex12.4% below
Price is 12.4% below Gekko Fair Value (more than 5% below).
See fair valueLeans bullish
Last 30 days: 1 unusual options signal.
See smart moneyReports in 99 days
Next report Feb 22, 2027, 99 days away — outside a typical 20-trading-day hold.
See earnings+7.7% on average
From this point in the calendar, the next 20 trading days averaged +7.7% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
BioMarin Pharmaceutical closed at $57.23 on Nov 13, 2026, +3.5% over the past year, inside a 52-week range of $49.26 to $70.98.
Use the left and right arrow keys to read daily values.
Put BMRN on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
BioMarin Pharmaceutical develops and sells medicines for people with rare, often life-threatening genetic and metabolic disorders. Its marketed products include enzyme replacement therapies such as Vimizim, Naglazyme, Brineura and Aldurazyme, along with Kuvan and Palynziq for phenylketonuria and Voxzogo for achondroplasia. The company is best known for this concentrated focus on treatments for small, clearly defined patient populations rather than broader disease categories.
Alongside its approved therapies, BioMarin runs a pipeline of experimental treatments, including a gene therapy for severe hemophilia A now in Phase III trials and earlier-stage gene therapy programs aimed at phenylketonuria and primary hyperoxaluria. It sells through specialty pharmacies, hospitals, government health agencies, and distributors and wholesalers, reaching patients and providers in the United States, Europe, Latin America and other regions. The company also works with outside partners, including Sarepta Therapeutics, Ares Trading, Catalyst Pharmaceutical Partners and Asubio Pharma, on licensing and collaborative projects.
BioMarin was founded in 1996 and is headquartered in San Rafael, California. Its shares are listed on the NASDAQ under the ticker BMRN.
BioMarin Pharmaceutical’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 57.6, in the Neutral zone, down 3.5 points over five sessions.
Down 3.5 points over five sessions, from the Accumulation zone.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 63 | +0.8% | +2.2% | ||
| Accumulation | 269 | −0.2% | −0.6% | ||
| Neutral (current zone) | 349 | −0.4% | −1.7% | ||
| Distribution | 18 | −1.9% | −6.2% | ||
| Selling | 3 | Too few readings yet | |||
Average BMRN share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
BioMarin Pharmaceutical trades 12.4% below Gekko Fair Value of $65.36, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what BioMarin Pharmaceutical shares are worth, recalculated every trading day.
$65.36
Gekko Fair Value, Nov 13, 2026
12.4% Undervalued
At the end of Sep 2026 the price was 13.1% below the estimate.
No open-market insider purchases were filed for BioMarin Pharmaceutical, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for BMRN in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in BMRN were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
BioMarin Pharmaceutical has been buying back its own shares.
From company filings.
1signal, 100% of the flagged premium in calls.
Latest: Bullish flow on Oct 21, $339K in unusual premium.
1of the funds Gekko tracks holds BMRN.
BioMarin Pharmaceutical reports on Feb 22, 2027, after the close (99 days away), and beat the EPS estimate in 6 of its last 8 reports.
Feb 22, 2027
Expected after the close, 99 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | $1.20 est $0.95 | $989.7M est $932.0M | +6.5% |
| May 4, 2026 | $0.76 est $0.91 | $766.0M est $752.5M | −1.5% |
| Feb 23, 2026 | $0.46 est $0.81 | $874.6M est $833.7M | −2.3% |
| Oct 27, 2025 | $0.12 est −$0.15 | $776.1M est $823.5M | −1.8% |
| Aug 4, 2025 | $1.44 est $0.86 | $825.4M est $761.9M | +6.5% |
| May 1, 2025 | $1.13 est $0.95 | $745.1M est $738.7M | −2.6% |
| Feb 19, 2025 | $0.92 est $0.74 | $747.0M est $712.3M | +6.0% |
| Oct 29, 2024 | $0.55 est $0.52 | $745.7M est $712.3M | −4.9% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for BioMarin Pharmaceutical is $90.78, +58.6% from the last close, from 23 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 23 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 13 | Morgan Stanley | $103 | +80.0% |
| Nov 13 | Evercore ISI | $120 | +109.7% |
| Nov 13 | Morgan Stanley | $103 | +80.0% |
| Nov 4 | H.C. Wainwright | $60 | +4.8% |
| Nov 4 | Barclays | $114 | +99.2% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, BioMarin Pharmaceutical averaged +7.7% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +2.5% | 3 of 5 |
| Next 10 trading days | +4.9% | 4 of 5 |
| Next 15 trading days | +6.7% | 3 of 5 |
| Next 20 trading days | +7.7% | 3 of 5 |
| Next 30 trading days | +10.5% | 5 of 5 |
For scale, BMRN’s typical 20-trading-day move in either direction is about 5.3%.
BioMarin Pharmaceutical’s market cap is $11.09B and revenue of $3.66B over the last twelve months.
Coverage of BioMarin Pharmaceutical this week reads positive: 3 positive, 0 neutral and 0 negative headlines.
BioMarin Pharmaceutical’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 19.9% below |
| GILDGilead Sciences | Neutral | 11.7% above |
| MRNAModerna | Neutral | 21.1% above |
| NTRANatera | Accumulation | 18.6% below |
| IQVIQVIA | Accumulation | 5.0% above |
| UTHRUnited Therapeutics | Neutral | 11.2% below |
A peer links to its own page where one exists.
BioMarin Pharmaceutical’s market cap is $11.09B at the Nov 13, 2026 close of $57.23, with 193.7M shares outstanding.
The consensus analyst 12-month price target for BioMarin Pharmaceutical is $90.78, +58.6% from the last close. Of the 23 firms that rated the stock in the last 90 days, 17 rate it a buy, 6 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate BioMarin Pharmaceutical is undervalued: the Nov 13, 2026 close of $57.23 is 12.4% below Gekko Fair Value of $65.36. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
BioMarin Pharmaceutical is expected to report on Feb 22, 2027, after the market closes (99 days away). Analysts expect earnings of $0.82 per share on revenue of $1.09B. BioMarin Pharmaceutical beat the earnings estimate in 6 of its last 8 reports, moving 4% on average across the report.
BioMarin Pharmaceutical’s 52-week high is $70.98 and its 52-week low is $49.26; it closed at $57.23 on Nov 13, 2026, +3.5% over the past year. Over the last five years the shares peaked at $117.77 on Jan 27, 2023.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (fair value, smart money, earnings risk and seasonality), 2 as mixed (trend and gekkoindex). The checklist is a description of current data, not a recommendation.
Gekko flagged 1 unusual options signal in BioMarin Pharmaceutical over the last 30 days, with $339K of flagged premium in calls and $0 in puts. The latest, bullish flow, was on Oct 21, 2026 with $339K in unusual premium. The signal-by-signal table is in Gekko.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.